Plasma Protease C1-Inhibitor Treatment Market Size, Share, Trends, Outlook, Growth Opportunities, and Forecast 2023 - 2030

Plasma Protease C1-Inhibitor Treatment Market is segmented By Drug Type (C1-Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor, Antagonist), By Dosage (Lyophilized, Liquid/Injectable), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Plasma Protease C1-Inhibitor Treatment Market Report Overview

The Plasma Protease C1-Inhibitor Treatment Market report analyzes the global market size, shares, recent trends, competitive intelligence, and future market outlook. Plasma Protease C1-Inhibitor Treatment is used for the treatment of hereditary angioedema (HAE), a rare genetic disorder that causes episodes of swelling in different areas of the body. The market is driven by the increasing prevalence of HAE and the rising demand for effective and safe treatment options in America is rising. Key players in the Plasma Protease C1-Inhibitor Treatment Market include CSL Behring, Shire Plc, Pharming Group N.V., and other prominent players operating in the market.

C1–INH is a type of potent inhibitor of the complement and direct contact activation systems, and its deficiency can lead to the manifestation of hereditary angioedema. Moreover, Replacement therapy with human plasma-derived C1–INH is an efficacious and safe treatment for this disease.

Plasma Protease C1-Inhibitor Treatment Market Scope and Summary

For more insights - Download the Sample

Plasma Protease C1-Inhibitor Treatment Market Dynamics and Trends

The plasma protease C1-inhibitor treatment market is driven by significant growth over the forecast period due to the growing incidence of the disease hereditary angioedema (HAE). As per the global umbrella organization for the world’s HAE patient groups, Hereditary angioedema is a life-threatening genetic disease with an incidence between 1 in 10,000 and 1 in 50,000 people according to HAE International (HAEi). Moreover, increasing R&D investments, the discovery of inhibitor drugs, rising product approvals promising pipeline drugs, and novel therapies for the treatment of hereditary angioedema are the few other factors driving the market globally.

Increasing Prevalence of Hereditary Angioedema (HAE)

Hereditary angioedema (HAE) is an autosomal dominant, life-threatening condition, manifesting as recurrent and self-limiting episodes of facial, laryngeal, genital, or peripheral swelling with abdominal pain secondary to intra-abdominal edema. Additionally, the availability of various treatment options for acute attacks and prophylaxis of HAE are authorized and available in the market.  Moreover, HAE causes a humanistic burden to patients, affecting both physical and mental health, which hurts education, career, and work productivity, and substantial economic burdens. Hence, the timely and proper use of disease-specific treatments could improve the patient’s quality of life and reduce disease-specific morbidity and mortality. Therefore, reducing costs associated with hospitalizations and emergency room visits.

Increasing Investments in the Research & Development Activities

There is rapid expansion in the R&D activities that key market players are involved in for the development of new C1-inhibitor deficiency drugs. This led to an overall increase in market growth during the forecast period.

COVID-19 Impact on Plasma Protease C1-Inhibitor Treatment Market Growth

The COVID-19 pandemic affected the economy globally. COVID-19 has directly affected production and demand, supply chain disruption, and financial impact. Moreover,  COVID-19 has directly impacted the manufacturers' supply chain worldwide and shut down production facilities to minimize the risk of virus spread. Also, the lockdown policies have strengthened the demand for various raw materials. There are various research institutes and biopharmaceutical companies that are engaged in studying the effects of plasma protease C1-inhibitors in treating significant systemic abnormalities in patients with COVID‐19. In April 2020, Pharming Group N.V. announced the encouraging results from five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia that was treated with RUCONEST (recombinant human C1 inhibitor) under a compassionate use program at the University Hospital Basel, Switzerland.

Thus, such positive results of the plasma protease C1-inhibitors in treating COVID-19 patients are anticipated to provide a significant growth opportunity for Plasma Protease C1-inhibitor Treatment Market.

Plasma Protease C1-Inhibitor Treatment Market Segment Analysis

Based on the drug type, the plasma protease C1-Inhibitor treatment market has been classified into C1-inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor, and Antagonist.

The autolyzed segment accounted for the highest market share in the global market

Among drug types, the C1-inhibitor segment is expected to hold a dominant position in the plasma protease C1-inhibitor treatment market, due to the robust number of drugs approved by the regulatory agencies. For instance, in June 2017, CSL Behring, a global biopharmaceutical company, received the U.S. Food and Drug Administration for HAEGARDA (C1 Esterase Inhibitor Subcutaneous (Human))

Based on the dosage type, the plasma protease C1-Inhibitor treatment market has been classified into lyophilized and liquid/injectable.

The lyophilized segment dominated the Global Plasma Protease C1-Inhibitor Treatment Market in 2019

lyophilized segment holds the leading market share on the back of the increasing practice of intravenous administration of drugs for the treatment of HAE. Furthermore, rising demand for intravenous C1 esterase inhibitor drugs in emerging markets of regions like the Asia Pacific and Latin America is expected to positively influence the lyophilized segment.

Although, the liquid/injectable segment is likely to hold a significant market share shortly due to several factors. This includes increasing demand for subcutaneous administration of drugs, cost-effectiveness, fewer adverse effects, and increased preference for Firazyr over Kalbitor by physicians. However, the expected launch of subcutaneous Cinryze, Berinert, and DX-2930 will further hamper the growth of the lyophilized segment. To stay competitive, companies are vying to introduce the subcutaneous variants of Cinryze and Berinet for prophylactic treatment which are expected to be commercially available by 2019 and 2018 respectively. Despite the liquid/injectable nature of Firazyr and Kalbitor, the side effects associated with them can hamper the liquid/injectable segment over the forecast period.

Plasma Protease C1-Inhibitor Treatment Market Geographical Share

Based on geography, the study analyzes the Plasma Protease C1-Inhibitor Treatment Market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America leads the global market throughout the forecast period.

North America holds the largest share in the global Plasma Protease C1-inhibitor market due to the rising Hereditary Angioedema (HAE) and increasing R&D investments. The other factors also include the presence of a well-established healthcare infrastructure, an increasing number of product approvals, and major market players providing effective treatment options to patients suffering from Hereditary Angioedema in North America.

According to Discover HAE, it is estimated that 6,000 people in the United States live with HAE currently. In June 2017, CSL Behring received U.S. Food and Drug Administration (FDA) approval for its HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]), the first and only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients. Hence all these factors are expected to drive the overall market in the United States.

Plasma Protease C1-Inhibitor Treatment Companies and Competitive Landscape

The plasma protease C1-inhibitor treatment market is highly competitive, owing to the presence of brands. The key plasma protease C1-inhibitor treatment market players which are contributing to the growth of the global market include Limited (CSL Behring LLC), Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings), Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Inc., Fresenius Kabi. The major players are adopting new product launches and expansion strategies for global growth in the Plasma Protease C1-Inhibitor Treatment Market

CSL Behring 

Overview: CSL Behring is a biopharmaceutical company, that manufactures plasma-derived and recombinant therapeutic products and provides them to people in more than 100 countries. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia and von Willebrand Disease; primary immune deficiencies (PIDD); hereditary angioedema; inherited respiratory disease; and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.

Product Portfolio: The Company’s portfolio comprises plasma protease C1-Inhibitor treatment

Why Purchase the Report?

• Visualize the plasma protease C1-Inhibitor treatment market segmentation composition by drug type, dosage, and region, highlighting the critical commercial assets and players.
• Identify commercial opportunities in the plasma protease C1-Inhibitor treatment market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of plasma protease C1-inhibitor treatment market - level 3 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in Excel for the key product of all major market players.

The global plasma protease C1-inhibitor treatment market report would provide access to an approx. 42 market data tables, 46 figures, and 180 pages.

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers